News

OMNIMED Announces Appointment of Hugh Dodson to Dual Role of Chief Financial Officer & Chief Operating Officer

Dodson to provide strategic guidance to secure new revenue streams, grow presence in value-based healthcare environment Hugh Dodson - CFO…

2 years ago

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of…

2 years ago

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based…

2 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the…

2 years ago

CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline

Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE’s FilterTool aims to fuel rapid,…

2 years ago

ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF

Fremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…

2 years ago

CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates

BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 years ago

Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting

Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic…

2 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on…

2 years ago

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of…

2 years ago